The Drug Pricing Fight Washington Gets Wrong Has Real Consequences for Louisiana

Louisiana families know what it feels like to stretch a budget. They know what it costs to fill a prescription. And most of them have no idea that a significant reason American drug prices are so high is that wealthy foreign governments — our own allies — have spent decades rigging the system to avoid paying their fair share.

That imbalance is now squarely in the crosshairs of the Trump administration, and Louisiana has every reason to pay close attention.

A recent analysis from Ambassador Jeffrey Gerrish, who served as Deputy U.S. Trade Representative from 2018 to 2020, lays out the problem with striking clarity. Countries across the European Union, the United Kingdom, Japan, and South Korea have spent years using price controls, bureaucratic delays, and veiled patent threats to artificially suppress what they pay American pharmaceutical companies for life-saving medicines. Germany and France routinely block coverage of more than half of newly approved drugs by declaring they offer "no added benefit." European governments drag out reimbursement decisions for up to 700 days — effectively denying patients access to treatments their own regulators have already approved. Japan subjects patented drugs to annual price cuts regardless of their clinical value. South Korea has not updated the cost-effectiveness threshold it uses to set drug prices since 2007.

The result is predictable and deeply unfair: American drug companies earn roughly three-quarters of their global profits right here in the United States, even though America represents only about a quarter of the world economy. The burden of funding the next generation of medical breakthroughs falls overwhelmingly on American patients and taxpayers. Louisiana patients included.

The good news is that President Trump has already demonstrated this problem is solvable. In December 2025, the administration struck a landmark deal with the United Kingdom — the first of its kind — in which UK officials agreed to raise the threshold used to determine drug coverage, reduce revenue clawbacks on American medicines, and double pharmaceutical spending over the next decade. That agreement will generate billions in additional revenue for American biotech companies, spurring domestic research, manufacturing, and job creation. U.S. Trade Representative Jamieson Greer has signaled more deals are coming. But deals require leverage, and that is exactly what a formal Section 301 investigation into foreign drug pricing practices would provide. If the investigation confirms — as the evidence strongly suggests — that foreign governments have systematically underpaid for American-made medicines, it would authorize the administration to pursue targeted enforcement actions, including tariffs, to bring those trading partners back to the table.

Some in Washington, however, are pushing a different approach: mandating that American drug companies sell their products at the same artificially low prices foreign governments impose. The political appeal is obvious, but the policy logic is exactly backwards. Importing foreign price controls would not fix the problem — it would surrender to it. Foreign governments could simply refuse to negotiate, sit back, and watch as American law automatically drags U.S. prices down to their artificially suppressed floor. That eliminates the very leverage that brought the UK to the table in the first place. Worse, it would gut the research and development budgets that fund the next generation of treatments. Drug companies forced to operate on European-style margins do not maintain American-scale R&D pipelines. The cures that do not get funded do not get found. Most Favored Nation pricing sounds tough, but in practice it is a handout to the same foreign governments that have been freeloading on American innovation for decades — and it would cost this country far more in foregone medical progress than it would ever save at the pharmacy counter.

This is not an abstract debate in Louisiana. LSU Health Shreveport recently announced plans to transform the former Sears property at Mall St. Vincent into a state-of-the-art research facility — a direct response to surging demand for lab space driven by growth in NIH grants and new faculty recruits. The institution already houses four Centers of Research Excellence and three NIH Centers of Biomedical Research Excellence, with concentrations in cancer, cardiovascular disease, neuroscience, and addiction. Researchers there are conducting the kind of translational work — from basic science to clinical trials — that turns laboratory discoveries into commercial therapies. That pipeline depends entirely on a national environment where drug development is financially viable. Suppress the returns on innovation through imported price controls, and you do not just hurt pharmaceutical company shareholders. You dry up the investment that funds the next grant cycle, the next clinical trial, the next faculty hire in Shreveport.

LSU Health New Orleans tells a similar story, anchoring a broader life sciences ecosystem that includes the Louisiana Cancer Research Center, Obatala Sciences, and a growing network of biotech startups and contract research organizations that collectively create thousands of jobs and draw hundreds of millions in federal research dollars into the state every year. Louisiana Economic Development has made life sciences a priority industry for exactly this reason — the sector punches well above its weight in terms of economic multiplier effects and long-term workforce development.

All of that is at risk if Washington gets the drug pricing fight wrong. Louisiana's congressional delegation should be pushing hard for the Section 301 investigation Gerrish recommends. It is the right tool, at the right moment, in the hands of an administration that has already shown it can use trade pressure to deliver real results. American patients deserve a system where the cost of medical innovation is shared fairly across the globe, not carried almost entirely on their backs. And Louisiana's growing life sciences economy deserves a policy environment where the next breakthrough gets developed here — not foreclosed because Washington decided to import the same price controls that let our trading partners freeride for thirty years.

The foreign freeloading has gone on long enough. The answer is leverage, not surrender.